Literature DB >> 1895409

Substrate specificity of recombinant human immunodeficiency virus integrase protein.

R L LaFemina1, P L Callahan, M G Cordingley.   

Abstract

Recombinant human immunodeficiency virus type 1 (HIV-1) integrase (IN) produced in Escherichia coli efficiently cleaves two nucleotides from the 3' end of synthetic oligonucleotide substrates which mimic the termini of HIV-1 proviral DNA. Efficient cleavage was restricted to HIV-1 substrates and did not occur with substrates derived from other retroviruses. Mutagenesis of the U5 long terminal repeat (LTR) terminus revealed only moderate effects of mutations outside the terminal four bases of the U5 LTR and highlighted the critical nature of the conserved CA dinucleotide motif shared by all retroviral termini. Integration of the endonuclease cleavage products occurs subsequent to cleavage, and evidence that the cleavage and integration reactions may be uncoupled is presented. Competition cleavage reactions demonstrated that IN-mediated processing of an LTR substrate could be inhibited by competition with LTR and non-LTR oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895409      PMCID: PMC249082     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  A 32,000-dalton nucleic acid-binding protein from avian retravirus cores possesses DNA endonuclease activity.

Authors:  D P Grandgenett; A C Vora; R D Schiff
Journal:  Virology       Date:  1978-08       Impact factor: 3.616

2.  The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro.

Authors:  R A Katz; G Merkel; J Kulkosky; J Leis; A M Skalka
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

3.  Vectors for selective expression of cloned DNAs by T7 RNA polymerase.

Authors:  A H Rosenberg; B N Lade; D S Chui; S W Lin; J J Dunn; F W Studier
Journal:  Gene       Date:  1987       Impact factor: 3.688

4.  Sequence requirements for integration of Moloney murine leukemia virus DNA in vitro.

Authors:  F D Bushman; R Craigie
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Moloney murine leukemia virus integration protein produced in yeast binds specifically to viral att sites.

Authors:  S Basu; H E Varmus
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Avian sarcoma and leukosis virus pol-endonuclease recognition of the tandem long terminal repeat junction: minimum site required for cleavage is also required for viral growth.

Authors:  D Cobrinik; R Katz; R Terry; A M Skalka; J Leis
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

7.  The avian retroviral integration protein cleaves the terminal sequences of linear viral DNA at the in vivo sites of integration.

Authors:  M Katzman; R A Katz; A M Skalka; J Leis
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

8.  Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.

Authors:  F D Bushman; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

9.  Retroviral DNA integration: structure of an integration intermediate.

Authors:  T Fujiwara; K Mizuuchi
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

10.  Construction and analysis of deletion mutations in the pol gene of Moloney murine leukemia virus: a new viral function required for productive infection.

Authors:  P Schwartzberg; J Colicelli; S P Goff
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

View more
  78 in total

1.  Substrate sequence selection by retroviral integrase.

Authors:  H Zhou; G J Rainey; S K Wong; J M Coffin
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes.

Authors:  K Gao; S L Butler; F Bushman
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

3.  Characterization of a replication-defective human immunodeficiency virus type 1 att site mutant that is blocked after the 3' processing step of retroviral integration.

Authors:  H Chen; A Engelman
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Correct integration of model substrates by Ty1 integrase.

Authors:  S P Moore; D J Garfinkel
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Patterns of sequence conservation at termini of long terminal repeat (LTR) retrotransposons and DNA transposons in the human genome: lessons from phage Mu.

Authors:  Insuk Lee; Rasika M Harshey
Journal:  Nucleic Acids Res       Date:  2003-08-01       Impact factor: 16.971

6.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.

Authors:  A Engelman; R Craigie
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Integration of human immunodeficiency virus DNA: adduct interference analysis of required DNA sites.

Authors:  F D Bushman; R Craigie
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

8.  Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.

Authors:  Supachai Sakkhachornphop; Carlos F Barbas; Rassamee Keawvichit; Kanlaya Wongworapat; Chatchai Tayapiwatana
Journal:  Hum Gene Ther       Date:  2012-05-08       Impact factor: 5.695

9.  An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Authors:  E Vicenzi; D S Dimitrov; A Engelman; T S Migone; D F Purcell; J Leonard; G Englund; M A Martin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain.

Authors:  T Masuda; V Planelles; P Krogstad; I S Chen
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.